A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
Part of paid clinical trials in Fairfax, Virginia.
- Sponsor
- Inova Health Care Services
- Study ID
- NCT06106360
- Status
- Recruiting
Conditions
- Hematological Malignancy
- Solid Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Locus Health iPhone App — DEVICEIn this pilot study patients are enrolled into three (3) different groups which will vary by the frequency of the queries being sent to the patients during their chemotherapy cycle. The patients will be separated into three groups of 33-34 patients each. Each group will have a different frequency of symptom questions sent to them via the Locus Health iPhone App to determine patient fatigue and the compliance impact of different query cadences. Patients will be assigned to these 3 groups sequentially since the platform could not assign patients to these three cohorts in a random manner.
Study Details
A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.
Key Dates
- Start date
- Oct 26, 2023
- Status verified
- Dec 2025
- Primary completion
- Nov 1, 2025
- Completion
- Jun 26, 2026
Study Design
- Enrollment
- 100 participants (estimated)
Arms
- Arm: 3 CohortsCohort 1: Daily from day 2 through the end of treatment cycle (n=34) Cohort 2: Daily days 2-9 then every third day through end of cycle (n=33) Cohort 3: Daily days 2-9 for all symptoms, every third day thereafter regarding 'pain' only through end of cycle (n=33)
Primary Outcome Measure
The Use of Locus Heath iPhone App and the Apple Watch by Participants Undergoing Outpatient Chemotherapy. [ Time Frame: 120 days or until the chemotherapy regimen has stopped, whichever is sooner ]
Central Contacts
- Elahe Mollapour(571) 472-4724
- Keary Jane't
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | Keary Jane't John Deeken, MD (PRINCIPAL_INVESTIGATOR) Jasmine Huynh, MD (SUB_INVESTIGATOR) Melisa Yacur, MD (SUB_INVESTIGATOR) |
Find similar trials in Fairfax, VA
By research site
Related Studies
- A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesPHASE1/PHASE2 · Recruiting · Eisai Inc. · Tucson, Arizona
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · ImmVira Pharma Co. Ltd · Gilbert, Arizona
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPHASE1 · Recruiting · Exelixis · Phoenix, Arizona
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionPHASE1 · Recruiting · Bristol-Myers Squibb · Phoenix, Arizona